1. Home
  2. PRCT vs AGIO Comparison

PRCT vs AGIO Comparison

Compare PRCT & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PROCEPT BioRobotics Corporation

PRCT

PROCEPT BioRobotics Corporation

HOLD

Current Price

$25.85

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$27.98

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRCT
AGIO
Founded
2009
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.6B
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
PRCT
AGIO
Price
$25.85
$27.98
Analyst Decision
Buy
Buy
Analyst Count
11
8
Target Price
$35.44
$37.63
AVG Volume (30 Days)
2.1M
664.7K
Earning Date
04-23-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
1.71
N/A
EPS
N/A
N/A
Revenue
$308,054,000.00
$43,011,000.00
Revenue This Year
$32.85
$75.68
Revenue Next Year
$24.66
$167.63
P/E Ratio
N/A
N/A
Revenue Growth
37.22
N/A
52 Week Low
$19.35
$22.24
52 Week High
$64.89
$46.00

Technical Indicators

Market Signals
Indicator
PRCT
AGIO
Relative Strength Index (RSI) 45.68 46.39
Support Level $19.35 $26.48
Resistance Level $29.24 $29.49
Average True Range (ATR) 1.94 1.06
MACD 0.24 -0.06
Stochastic Oscillator 56.22 29.67

Price Performance

Historical Comparison
PRCT
AGIO

About PRCT PROCEPT BioRobotics Corporation

PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Share on Social Networks: